IN THE CLAIMS:

This listing of claims below will replace all prior versions, and listings, of claims in the application:

Listing of Claims

Claims 1 to 22 (Canceled)

Claim 23. (Currently amended) A method of treating premature ejaculation, the method comprising administering to a subject in need of such treatment a composition comprising an antidepressant by pulmonary inhalation ~~as claimed in claim 1~~.

Claim 24 (Original) A method as claimed in claim 23, wherein the method does not cause the adverse side effects normally associated with the administration of the antidepressant.

Claims 25 to 30 (Canceled)

Claim 31 (Previously presented) The method of claim 23, wherein adverse side effects, if any, provoked by the administration of the composition by inhalation are such that they would easily be tolerated by an average recipient.

Claims 32 to 37 (Canceled)

Claim 38. (New) A method as claimed in claim 23, wherein the antidepressant is a tricyclic antidepressant.

Claim 39. (New) A method as claimed in claim 23, wherein the composition comprises two or more antidepressants.

Claim 40. (New) A method as claimed in claim 23, wherein the composition comprises a further therapeutic agent, which is not an antidepressant.

Claim 41. (New) A method as claimed in claim 40, wherein the further therapeutic agent is also effective in treating PE.

Claim 42. (New) A method as claimed in claim 40, wherein the further therapeutic agent is a benzodiazepine.

Claim 43 (New) A method as claimed in claim 23, wherein the composition provides a dose of antidepressant of less than about 25mg.

Claim 44. (New) A method as claimed in claim 23, wherein the composition provides an onset of the therapeutic effect within no more than 30 minutes following pulmonary administration.

Claim 45. (New) A method as claimed in claim 23, wherein the composition is a dry powder composition.

Claim 46. (New) A method as claimed in claim 45, wherein the composition comprises particles of antidepressant having a mass median aerodynamic diameter of about 10μm or less.

Claim 47. (New) A method as claimed in claim 46, wherein the mass median aerodynamic diameter is about 5 μm or less.

Claim 48. (New) A method as claimed in claim 45, wherein at least 90% of the antidepressant has a particle size of about 10 μm or less.

Claim 49. (New) A method as claimed in claim 48, wherein at least 90% of the antidepressant has a particle size of about 5 μm or less.

Claim 50. (New) A method as claimed in claim 45, wherein the composition further comprises an additive material.

Claim 51. (New) A method as claimed in claim 50, wherein the additive material is provided

in an amount from about 0.15% to about 5% of the medicament, by weight.

Claim 52. (New) A method as claimed in claim 50, wherein the additive material is selected from the group consisting of leucine, magnesium stearate, lecithin, and sodium stearyl fumarate.

Claim 53. (New) A method as claimed in claim 45, wherein the composition further comprises an excipient material.

Claim 54. (New) A method as claimed in claim 53, wherein the excipient material is in the form of carrier particles having an average particle size of about 40 to about 70 μm.

Claim 55 (New) A method as claimed in claim 23, wherein the composition comprises a solution pMDI formulation including a propellant, a solvent and water.

Claim 56 (New) A method as claimed in claim 23, wherein the composition is a suspension pMDI formulation including a propellant.

Claim 57 (New) A method as claimed in claim 56, wherein the propellant is selected from the group consisting of: HFA134a, HFA227 and a combination thereof.

Claim 58. (New) A method as claimed in claim 23, wherein adverse side effects, if any, provoked by the administration of the medicament by inhalation are such that they would easily be tolerated by an average recipient.

Claim 59. (New) A method as claimed in claim 23, wherein the composition provides a dose of antidepressant of less than about 15mg.

Claim 60. (New) A method as claimed in claim 23, wherein the composition provides a dose of antidepressant of less than about 5mg.

Claim 61. (New) A method as claimed in claim 23, wherein the composition provides an onset of the therapeutic effect within no more than 20 minutes following pulmonary administration.

Claim 62. (New) A method as claimed in claim 23, wherein the composition provides an onset of the therapeutic effect within no more than 10 minutes following pulmonary administration.

Claim 63. (New) A method as claimed in claim 23, wherein the composition provides an onset of the therapeutic effect within no more than 5 minutes following pulmonary administration.

Claim 64. (New) A method as claimed in claim 23, wherein the composition provides an onset of the therapeutic effect within no more than 1 minute following pulmonary administration.